AMENDMENTS TO CLAIMS

Claim 1. (Cancelled).

Claims 2 and 3. (Cancelled).

Claim 4. (Cancelled).

Claim 5. (Currently Amended) A pharmaceutical composition comprising a core in the form of a beadlet and an enteric coating for said core, said core comprising about 80% to about 100% by weight of an acid labile medicament which is 2′,3′-dideoxyinosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder selected from the group consisting of sodium carboxymethylcellulose, hydroxypropylmethylcellulose, potassium alginate, sodium alginate and partially pregelatinized corn starch, said composition being devoid of a protective coat or subcoat between the core and the enteric coating, wherein the weight ratio of enteric coating to core is between about 0.05:1 to about 0.6:1, and wherein the enteric coating should provide protection of the medicament at a pH less than 3 but will permit drug release at a pH of 4.5 or higher.

Claims 6 and 7. (Cancelled).

Claim 8. (Original) The pharmaceutical composition of Claim 5 wherein said enteric coating comprises a polymer and a plasticizer.

Claim 9. (Original) The pharmaceutical composition of Claim 8 wherein said polymer is selected from the group consisting of hydroxypropylmethylcellulose phthalate, polyvinyl acetate phthalate and cellulose acetate phthalate.

Claim 10. (Original) The pharmaceutical composition of Claim 8 wherein said polymer comprises a methacrylicacid copolymer.

Claim 11. (Original) The pharmaceutical composition of Claim 10 wherein said enteric coating includes the methacrylic acid copolymer in an amount within the range of from about 5 to

about 30% of the total composition weight, and said plasticizer in an amount within the range from about 0.5 to about 6% of the total composition weight.

Claim 12. (Original) The pharmaceutical composition of Claim 10 wherein said methacrylic acid copolymer is methacrylic acid copolymer.

Claim 13. (Original) The pharmaceutical composition of Claim 8 wherein said plasticizer is triethyl citrate, triacetin, tributyl sebecate, or polyethylene glycol.

Claim 14. (Original) The pharmaceutical composition of Claim 8 wherein said plasticizer is diethyl phthalate.

Claim 15. (Previously Presented) The pharmaceutical composition of Claim 8 wherein said enteric coating includes methacrylic acid copolymer and diethyl phthalate.

Claim 16. (Original) The pharmaceutical composition of Claim 5, further comprising an anti-adherent coating disposed on the exterior of said enteric coating.

Claim 17. (Original) The pharmaceutical composition of Claim 16 wherein said anti-adherent coating is a hydrophobic material.

Claim 18. (Original) The pharmaceutical composition of Claim 17 wherein the anti-adherent coating is magnesium stearate or fumed silica.

Claim 19. (Original) The pharmaceutical composition of Claim 18 wherein the anti-adherent coating is talc.

Claim 20. (Original) The pharmaceutical composition of Claim 16 wherein said anti-adherent is present in an amount within the range from about 0.1% to about 4.0% of the total composition weight.

Claim 21. (Currently Amended) The pharmaceutical composition of Claim 5 wherein said disintegrant is cross-linked sodium carboxymethylcellulose, corn starch, or cross linked ~~polyvinlpyrrolidone~~ polyvinylpyrrolidone.

Claim 22. (Original) The pharmaceutical composition of Claim 5 wherein said disintegrant is sodium starch glycolate.

Claim 23. (Original) The pharmaceutical composition of Claim 5 wherein said binder is alkaline.

Claim 24. (Previously Presented) The pharmaceutical composition of Claim 23 wherein said binder is sodium carboxymethylcellulose.

Claims 25 and 26. (Cancelled).

Claim 27. (Currently Amended) ~~The~~ A pharmaceutical composition ~~of Claim 5~~ comprising a core in the form of a beadlet and an enteric coating for said core, wherein said core comprises about 95% by weight 2′,3′-dideoxyinosine, about 1% by weight sodium carboxymethylcellulose and about 4% by weight sodium starch glycolate.

Claim 28. (Previously Presented) The pharmaceutical composition of Claim 5 wherein said composition is encapsulated in a capsule for oral administration.

Claim 29. (Currently Amended) The pharmaceutical composition of Claim 28 wherein said capsule is filled with said composition in an amount equivalent to attain a dosage of ~~ddI~~ 2′,3′-dideoxyinosine required for twice daily administration.

Claim 30. (Currently Amended) The pharmaceutical composition of Claim 28 wherein said capsule is filled with said composition in an amount equivalent to attain a dosage of ~~ddI~~ 2′,3′-dideoxyinosine required for once daily administration.

Claim 31. (Original) A pharmaceutical composition comprising:

a) a dissolvable capsule; and

b) the pharmaceutical composition of Claims 5, 16, or 27 which is encapsulated within said dissolvable capsule.

Claims 32 to 53. (Cancelled).